Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × lorlatinib × Thoracic × Clear all

Phase

Status

Sponsor Class

OTHER 22 INDUSTRY 15 OTHER_GOV 1 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 12 Carboplatin 11 Pemetrexed 10 Drug Therapy 9 Gemcitabine 8 Gefitinib 8 Docetaxel 7 camrelizumab 5 Radiotherapy 5 Paclitaxel 5 Nivolumab 5 Irinotecan 5 Erlotinib Hydrochloride 5 tislelizumab 4 apatinib 4 Simvastatin 4 Endostatins 4 Bevacizumab 4 pembrolizumab 3 endostar protein 3 Platinum Compounds 3 Etoposide 3 toripalimab 2 surufatinib 2 olaparib 2 durvalumab 2 atezolizumab 2 anlotinib 2 Topotecan 2 Thalidomide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

National Cancer Center, Korea

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡